Developer docs
API playgroundTry for free, no card

Search company profiles

Coral Genomics

Full company profile

uuid0000j73

Namestring
Coral Genomics
Legal namestring
JANJI33
Company typeenum
Private
Founded yearint
2025
Descriptiontext

Coral Genomics is a privately held, for-profit company headquartered in San Francisco, California, founded in 2018. The company develops clinical tests intended to help healthcare providers streamline the prior authorization process and select effective medications for patients. Its offering sits at the intersection of genomics-based diagnostics and clinical workflow automation, targeting two tightly coupled pain points in U.S. healthcare delivery: payer prior authorization friction and therapy selection.

The company is led by co-founder and CEO Atray Dixit and Chief Scientific Officer Kasey Davis, and operates with a lean team of 1–10 employees. To date, Coral Genomics has assembled approximately $5.7 million in capital, the majority of which is non-dilutive grant funding — a $2.0 million award from the National Human Genome Research Institute (NHGRI) in October 2020 and a $1.7 million award from the National Institutes of Health (NIH) in January 2021 — supplemented by a $2.0 million seed equity round in 2019 led by 8VC, Soma Capital, and Y Combinator. The grant-heavy capital structure is consistent with a pre-commercial R&D posture rather than a scaled go-to-market motion.

No information is disclosed regarding specific product SKUs, pricing, payer contracts, provider customers, regulatory clearances, partnerships, or revenue. This data gap constrains any deeper commercial or competitive assessment; the company should be treated as an early-stage, R&D-oriented entity whose commercial profile has not yet been validated in the available record.

Short descriptiontext

Coral Genomics is a privately held San Francisco-based company founded in 2018 that develops clinical tests to help healthcare providers streamline prior authorization and select effective medications. It operates at an early stage with 1–10 employees.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
clinical decision support, genomics testing, prior authorization, pharmacogenomic testing, precision medicine
Industry2 codes
PRIMARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Clinical Decision Support Software
Social media profiles1 record
Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Coral develops new clinical tests that help healthcare providers streamline prior authorization and select the effective medication for patients. The offering combines genomics-based testing with clinical decision support functionality to reduce administrative friction and improve prescribing accuracy for provider organizations.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Coral Clinical Tests
CategoryClinical Decision Support
Description

A genomics-based clinical test offering that helps healthcare providers streamline the prior authorization process and select the most effective medication for patients. Targeted at provider organizations (hospitals, clinics, group practices) seeking to reduce administrative friction and improve prescribing accuracy.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Provides clinical decision support software that analyzes a patient's genomic and clinical data to guide drug selection and avoid adverse events — directly comparable to Coral's medication-selection positioning.

TypeDirect peer
Description

Operates a clinical-grade genetic testing platform that returns results integrated into provider workflows, with employer and payer partnerships — comparable clinical-genomics infrastructure and GTM model.

TypeDirect peer
Description

Clinical DNA sequencing platform with an integrated population-health and pharmacogenomics pipeline; comparable as a sequencing-enabled clinical testing company serving providers and payers.

4Tempus AI
TypeBroad incumbent
Description

Large precision medicine company offering molecular testing and clinical decision support across oncology and other therapeutic areas — overlaps with Coral's biomarker-driven drug selection thesis but at much broader scale.

TypeBroad incumbent
Description

Established clinical genetic testing company with reimbursed pharmacogenomic and disease-risk tests — comparable end market (providers/payers) and test-driven revenue model, but with a much broader menu.

TypeBroad incumbent
Description

Roche-owned provider of comprehensive genomic profiling tests whose results guide therapy selection, particularly in oncology — comparable as evidence-based testing informing drug choice.

TypeDirect peer
Description

Pharmacogenomic testing company focused on mental health medication selection and response prediction — closely comparable to Coral's medication-selection positioning within a specific therapeutic area.

8CoverMyMeds
TypeEmerging player
Description

McKesson-owned prior authorization automation platform widely used by U.S. providers and pharmacies — adjacent rather than direct, since it does not run the lab tests themselves, but represents the workflow Coral would integrate with.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Coral Genomics

Clinical Decision Support Softwarecoralgenomics.com

Coral Genomics is a privately held San Francisco-based company founded in 2018 that develops clinical tests to help healthcare providers streamline prior authorization and select effective medications. It operates at an early stage with 1–10 employees.

What Coral Genomics does

Coral Genomics is a privately held, for-profit company headquartered in San Francisco, California, founded in 2018. The company develops clinical tests intended to help healthcare providers streamline the prior authorization process and select effective medications for patients. Its offering sits at the intersection of genomics-based diagnostics and clinical workflow automation, targeting two tightly coupled pain points in U.S. healthcare delivery: payer prior authorization friction and therapy selection.

The company is led by co-founder and CEO Atray Dixit and Chief Scientific Officer Kasey Davis, and operates with a lean team of 1–10 employees. To date, Coral Genomics has assembled approximately $5.7 million in capital, the majority of which is non-dilutive grant funding — a $2.0 million award from the National Human Genome Research Institute (NHGRI) in October 2020 and a $1.7 million award from the National Institutes of Health (NIH) in January 2021 — supplemented by a $2.0 million seed equity round in 2019 led by 8VC, Soma Capital, and Y Combinator. The grant-heavy capital structure is consistent with a pre-commercial R&D posture rather than a scaled go-to-market motion.

No information is disclosed regarding specific product SKUs, pricing, payer contracts, provider customers, regulatory clearances, partnerships, or revenue. This data gap constrains any deeper commercial or competitive assessment; the company should be treated as an early-stage, R&D-oriented entity whose commercial profile has not yet been validated in the available record.

Coral Genomics firmographics

Firmographics
Name
Coral Genomics
Legal name
JANJI33
Website
https://coralgenomics.com
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
1–10 employees
Short description
Coral Genomics is a privately held San Francisco-based company founded in 2018 that develops clinical tests to help healthcare providers streamline prior authorization and select effective medications. It operates at an early stage with 1–10 employees.
Ownership category
akta.pro rank

Coral Genomics industry classification

Industry
Product category
Clinical Decision Support Software
NAICS
Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Clinical decision support
  • Genomics testing
  • Prior authorization
  • Pharmacogenomic testing
  • Precision medicine

Where Coral Genomics is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Markets served

Coral Genomics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Coral Genomics product offering

Product offering

Core offering

Coral develops new clinical tests that help healthcare providers streamline prior authorization and select the effective medication for patients. The offering combines genomics-based testing with clinical decision support functionality to reduce administrative friction and improve prescribing accuracy for provider organizations.

Differentiator

Problem solved

Functional benefit

Products and services

  • Coral Clinical Tests A genomics-based clinical test offering that helps healthcare providers streamline the prior authorization process and select the most effective medication for patients. Targeted at provider organizations (hospitals, clinics, group practices) seeking to reduce administrative friction and improve prescribing accuracy.

Companies that use Coral Genomics

Customer profile

Ideal customer profiles1 record

Coral Genomics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Coral Genomics partnerships and signals

Strategic signal

Recent moves4 records

Expansion highlights2 records

Coral Genomics competitors and assessment

Company assessment

Direct peers

  • Molecular Health: Provides clinical decision support software that analyzes a patient's genomic and clinical data to guide drug selection and avoid adverse events — directly comparable to Coral's medication-selection positioning.
  • Color Health: Operates a clinical-grade genetic testing platform that returns results integrated into provider workflows, with employer and payer partnerships — comparable clinical-genomics infrastructure and GTM model.
  • Helix: Clinical DNA sequencing platform with an integrated population-health and pharmacogenomics pipeline; comparable as a sequencing-enabled clinical testing company serving providers and payers.
  • Genomind: Pharmacogenomic testing company focused on mental health medication selection and response prediction — closely comparable to Coral's medication-selection positioning within a specific therapeutic area.

Broad incumbents

  • Tempus AI: Large precision medicine company offering molecular testing and clinical decision support across oncology and other therapeutic areas — overlaps with Coral's biomarker-driven drug selection thesis but at much broader scale.
  • Myriad Genetics: Established clinical genetic testing company with reimbursed pharmacogenomic and disease-risk tests — comparable end market (providers/payers) and test-driven revenue model, but with a much broader menu.
  • Foundation Medicine: Roche-owned provider of comprehensive genomic profiling tests whose results guide therapy selection, particularly in oncology — comparable as evidence-based testing informing drug choice.

Emerging players

  • CoverMyMeds: McKesson-owned prior authorization automation platform widely used by U.S. providers and pharmacies — adjacent rather than direct, since it does not run the lab tests themselves, but represents the workflow Coral would integrate with.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights4 records

Customer concentration

Coral Genomics social profiles

Digital presence

Coral Genomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Coral Genomics leadership team

Management profile

Number of profiles

Profiles2 records

Coral Genomics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Coral Genomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Coral Genomics

What does Coral Genomics do?

Coral develops new clinical tests that help healthcare providers streamline prior authorization and select the effective medication for patients. The offering combines genomics-based testing with clinical decision support functionality to reduce administrative friction and improve prescribing accuracy for provider organizations.

Is Coral Genomics a public or private company?

Coral Genomics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Coral Genomics founded?

Coral Genomics was founded in 2025. It employs 1 to 10 people.

Where is Coral Genomics based?

Coral Genomics is headquartered in San Francisco, United States, in the North America region.

Who are Coral Genomics's main competitors?

Direct peers on record are Molecular Health, Color Health, Helix and Genomind. Broad incumbents are Tempus AI, Myriad Genetics and Foundation Medicine. CoverMyMeds is listed as an emerging player.

Does Coral Genomics have an API?

No public API is recorded for Coral Genomics.

What industry is Coral Genomics in?

Coral Genomics's product category is Clinical Decision Support Software. Its primary akta.pro industry code is HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics), with a secondary code of HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals